SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Decentraland

Decentraland (MANA) is trending amidst intense community speculation surrounding potential Apple partnerships and Apple Pay integration, with the token recently noted as #1 on Stocktwits. Enthusiasts are actively calling for a major metaverse sector revival, anticipating significant future gains and debating the project's potential to re-approach its previous all-time highs.

Perpetua Resources Corp. is an exploration and development stage company that engages in acquiring mining properties with the intention of exploring, evaluating and placing into production. Its principal business is the exploration, redevelopment, restoration and operation of the Stibnite Gold Project in Idaho, USA. The firm's mineral project is the Stibnite Gold Project, which contains mineral deposits and focuses to explore, evaluate and redevelop all of the deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project. The company was founded in the year 1899 and is headquartered in Donnelly, ID.

Perpetua Resources Corp.

Perpetua Resources is trending as it advances its Stibnite Gold Project, fueled by significant strategic equity investments and preliminary terms for substantial U.S. EXIM debt financing. The company's progress, including federal approval and the start of early construction, highlights its role as a critical domestic source of antimony for defense and technology sectors, drawing investor attention amid national security initiatives and broader critical mineral supply chain concerns.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amidst a recent analyst downgrade that many in the community believe is an orchestrated effort to depress the stock price. Despite this, investors are actively discussing the company as a deep value opportunity, citing its strong dividend yield and defensive food staples appeal, especially with a strategic separation into two entities and new leadership on the horizon. There's anticipation that this restructuring could unlock significant intrinsic value, despite current market sentiment.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer ($ICP) is trending as the community discusses its "Mission 70" initiative, aiming to significantly reduce token inflation through increased network usage and token burns from projects like Caffeine.ai. While proponents emphasize ICP's unique full-stack on-chain technology and growing ecosystem, others express frustration over past price performance and ongoing supply concerns. The debate centers on whether its advanced utility and potential for institutional adoption will translate into sustained value.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon has recently experienced a significant investor reaction to its decision to cut its dividend to prioritize debt reduction, following an internal probe into sales practices that led to its CEO's resignation. Despite these challenges, the community is actively debating its substantial long-term value, citing multiple new biosimilar approvals and promising growth in its women's health portfolio like VTAMA cream as potential catalysts for recovery and appreciation from its low valuation.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is currently trending due to its recent strategic partnership with World Liberty Financial and the anticipated launch of its Super App, which includes new staking features. The community is overwhelmingly bullish, drawing strong parallels to the early growth of major utility tokens like XRP and XLM, driven by ZBCN's ISO 20022 and MiCA compliance for real-world financial applications.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending after undergoing a reverse stock split to regain NASDAQ compliance and a strategic shift prioritizing early-stage ADC programs over its former lead asset, Luvelta. This move has ignited community debate, with investors expressing frustration over the company's direction and cash burn, while others see it as deeply undervalued, anticipating future partnerships and pipeline milestones to drive a rebound.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is currently trending due to the recent mainnet launch and anticipation of its imminent Coinbase listing, following strong endorsements from former Google CEO Eric Schmidt. The community is actively discussing its potential as a high-throughput Layer-1 blockchain designed for compliant real-world asset tokenization and institutional financial settlement. Many view KTA as a foundational project poised to bridge traditional finance with crypto, leading to considerable long-term optimism despite recent price fluctuations.

Valkyrie ETF Trust II - CoinShares Bitcoin Mining ETF

CoinShares Bitcoin Mining ETF

CoinShares Bitcoin Mining ETF (WGMI) is trending amidst a rallying crypto market, fueled by Bitcoin's strong price action and significant sector developments. Investors are actively discussing the ETF's resilience and its underlying holdings' strategic pivot towards high-performance computing and AI data center operations. This diversification is viewed as a key growth driver, with many seeing WGMI as a less volatile, comprehensive way to gain exposure to both the expanding Bitcoin ecosystem and the lucrative AI infrastructure buildout.

Restaurant Brands International, Inc. is a holding company, which engages in the operation of quick service restaurants. It operates through the following segments: Tim Hortons, Burger King, Popeyes, and Firehouse Subs. The Tim Hortons segment provides donut, coffee, and tea restaurant services. The Burger King segment manages fast food hamburger restaurant. The Popeyes segment handles chicken category of the quick service segment of the restaurant industry. The company was founded on August 25, 2014 and is headquartered in Toronto, Canada.

Restaurant Brands International Inc

Restaurant Brands International (QSR) is trending amid ongoing strategic efforts to revitalize its core brands, notably the recent acquisition of its largest Burger King franchisee and accelerated remodels for Burger King U.S., alongside international expansion for Popeyes and Tim Hortons. The community is actively discussing the early positive impact of these initiatives, citing strong sales growth across its portfolio and an optimistic outlook on the company's long-term growth trajectory in a competitive quick-service restaurant market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Oppenheimer downgraded Mosaic to ‘Perform’ from ‘Outperform’.</li><li>Tight sulfur market conditions are expected to persist into the first half of 2026, continuing to weigh on Mosaic’s outlook, the brokerage firm added.</li><li>Tight credit and increased competition due to an influx of lower-grade phosphate imports from China weighed on demand and margins in Brazil.</li></ul>Mosaic Company (MOS) shares were trading down 4.5% on Friday after the firm said that fertilizer market conditions remained challenging in the fourth quarter (Q4) of 2025, as weaker-than-usual seasonal demand weighed on results.In response, Oppenheimer downgraded Mosaic to ‘Perform’ from ‘Outperform’ and removed the firm’s previous $35 price target following the company’s “weak” preliminary Q4 results.Oppenheimer expects Mosaic to continue making gradual progress on operating rates, but noted there is no clear catalyst to lift fertilizer demand in the current crop year. Tight sulfur market conditions are also expected to persist into the first half of 2026, continuing to weigh on the outlook.Despite the intraday drop, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours.<h2 class="st-heading-2">Q4 Preliminary Update</h2>In North America, fertilizer demand dropped sharply as growers remained under economic pressure and an early winter shortened the fall application season. Phosphates were hit hardest due to lower affordability than potash, with shipments estimated to be down about 20% from a year ago.The weak environment weighed on Mosaic’s results, with Q4 phosphate sales of about 1.3 million tonnes and potash sales near 2.2 million tonnes. In response, the company adjusted its phosphate production and shifted volumes to markets showing stronger demand, keeping overall output in line with the prior quarter, though lower sales and rising inventories pressured cash flow.Conditions in Brazil also worsened, as tighter credit and increased competition, due to an influx of lower-grade phosphate imports from China, weighed on demand and margins. As a result, Mosaic Fertilizantes’ sales fell short of expectations, even as full-year volumes were roughly flat.Looking ahead, Mosaic sees a more favorable setup in 2026, supported by nutrient replenishment needs, government support programs, tightening phosphate markets, and reduced Chinese exports, all of which could help lift demand and prices over time, it said.The company is expected to post its Q4 2025 results on February 24.Over the past year, <a href="https://stocktwits.com/symbol/MOS">MOS stock</a> has declined nearly 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-abus-stock-fall-today/cmUlzXeR4BY">ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Mosaic Company logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MOS Stock Sees Red As Cheaper Chinese Imports Weigh On Q4 Operations

Mosaic Company said that fertilizer market conditions remained challenging in the fourth quarter, as weaker-than-usual seasonal demand weighed on results.

Equity

Mosaic Company said that fertilizer market conditions remained challenging in the fourth quarter, as weaker-than-usual seasonal demand weighed on results.


3 Basic Materials Funds to Buy as Cyclical Tailwinds Build

FSDPX, FKRCX and ACGGX stand out as materials funds as cyclical tailwinds, pricing power and commodity demand point to a stronger 2026.

Should You Invest in the State Street Materials Select Sector SPDR ETF (XLB)?

Top-Ranked ETFs to Power Your Portfolio Higher 

With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Notable ETF Outflow Detected - XLB, NEM, ECL, NUE

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Materials Select Sector SPDR Fund (Symbol: XLB) where we have...

Noteworthy ETF Outflows: XLB, ECL, MLM, FCX

See Which Of The Latest 13F Filers Holds XLY

At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2025 reporting period, and noticed that The Materials Select Sector SPDR Fund (Symbol: XLY) was...

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient deaths involving the treatment.&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://stockwits.com/symbol/SRPT">Sarepta’s stock</a> plummeted more than 26% in midday trade on Friday. However, on Stocktwits, retail sentiment around the company remained in ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter.A separate&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-request-sarepta-stop-all-shipments-gene-therapy-elevidys-source-says-2025-07-18/#:~:text=The%20FDA's%20request%20follows%20the,condition%20called%20Duchenne%20muscular%20dystrophy.">report</a> by Reuters said that the FDA plans to request Sarepta to stop all shipments of Elevidys voluntarily.Makary’s comments during an&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/fda-is-investigating-if-sarepta-s-elevidys-should-stay-on-market">interview</a> with Bloomberg come after the company on Thursday disclosed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">third patient death</a> in a clinical trial involving a different experimental gene therapy that uses a similar viral delivery system.&nbsp;A company spokesperson&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.The FDA had already been investigating two earlier deaths linked to Elevidys.The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for gene treatments that use adeno-associated viral (AAV) vectors. Elevidys, which was granted accelerated approval in 2023 for Duchenne muscular dystrophy, has remained on the market under post-approval study requirements.Bloomberg also reported that the latest death resulted in an unusually tense exchange between analysts and Sarepta executives on a Friday call. The same group of analysts reportedly had a call with the company earlier this week about the future of Elevidys, but the firm failed to disclose the third patient death. On Friday, two of the analysts asked executives whether the company was keeping any other fatalities undisclosed.“We are historically a very transparent organization,” said Sarepta CEO Douglas Ingram, according to the report, adding that the company didn’t disclose the third patient death earlier because “it was neither material nor central” to what was being discussed.&nbsp;Sarepta’s stock is down 88% year-to-date and nearly 90% over the past 12 months.Get updates to this developing story directly on Stocktwits.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grubhub-owner-wonder-reportedly-in-talks-for-500-m-debt-refinancing/ch8kHoKR5qp">Grubhub Owner Wonder Reportedly In Talks For $500M Debt Refinancing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market

The FDA had already been investigating two earlier deaths linked to Elevidys.

President Donald Trump’s confirmation of a 50% tariff on copper imports sent U.S. copper futures and mining stocks – including Freeport-McMoran (FCX) and Southern Copper (SCCO) – sharply higher Tuesday. He also said that tariffs targeting the pharmaceutical and semiconductor sectors would be next on the docket.“We’re going to be announcing pharmaceuticals, chips, and various couple of other things — big one,” Trump told reporters at a White House cabinet meeting. “Now today we’re doing copper… I believe the tariff on copper, we’re going to make it 50%.”U.S. copper futures jumped more than 10% on the news, while&nbsp;<a href="http://stocktwits.com/symbol/FCX">Freeport-McMoran’s stock</a> rallied nearly 5%. On Stocktwits, retail sentiment around Freeport-McMoRan edged higher within ‘bullish’ territory as chatter jumped to ‘high’ levels from ‘normal’ a day ago.&nbsp;<a href="http://stocktwits.com/symbol/SCCO">Southern Copper’s stock</a> also gained more than 1% following the announcement, and&nbsp;In February, the Trump administration launched a Section 232 investigation into copper imports, citing potential national security concerns. That probe is due to conclude by November.During the cabinet meeting, Agriculture Secretary Brooke Rollins also raised alarms about Chinese ownership of U.S. farmland, calling it a “massive national security issue.”&nbsp;She said China has been acquiring land near U.S. military bases and urged Congress to ban such purchases. “There’s an executive order coming and some other things coming behind that,” she added.Despite the tough stance on trade and foreign investment, Trump said U.S.-China relations remain stable. “They’ve been very fair on our trade deal, honestly,” he said, adding that he maintains regular communication with Chinese President Xi Jinping. “I’m getting along with President Xi very well. We speak often.”Markets remained mixed after Trump’s cabinet meeting. The&nbsp;<a href="http://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a> edged 0.05% higher, while the&nbsp;<a href="http://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Index ETF (DIA)</a> remained down by 0.27%. Meanwhile, the&nbsp;<a href="http://stocktwits.com/symbol/QQQ">Invesco QQQ Trust Series 1 (QQQ)</a>, which tracks the tech-heavy Nasdaq 100, gained 0.2%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-eu-trade-deal-two-days-off-predicts-300-b-tariff-revenue/chFvyNrR5WM">Trump Says EU Trade Deal ‘Two Days Off’, Predicts $300B In Tariff Revenue By Year-End</a>

U.S. President Donald Trump speaks to members of the press during a Cabinet Meeting at the White House on July 08, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Copper Prices Surge After Trump Says 50% Tariff Is Coming – Pharma And Chip Levies Next

President Donald Trump also said U.S.-China relations remain stable and that he’s getting along with Chinese President Xi Jinping “very well.” 

Goldman Sachs ups S&P 500 targets on supportive policy, long-term earnings outlook

Investing.com -- Goldman Sachs raised its S&P 500 forecasts across the board, reflecting more supportive macro conditions and investor confidence in long-term (LT) earnings growth.

XLB
Materials Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLB News

XLBMaterials Select Sector SPDR Fund